Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))

Bruix J.ANN-LII CHENGMeinhardt G.Nakajima K.De Sanctis Y.Llovet J.2021-08-312021-08-3120180168-8278https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051650852&doi=10.1016%2fj.jhep.2018.07.015&partnerID=40&md5=6dccbd21a2ab02f5bcdc22ade1739d45https://scholars.lib.ntu.edu.tw/handle/123456789/580063[SDGs]SDG3Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))corrigendum10.1016/j.jhep.2018.07.015301040262-s2.0-85051650852